Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601818 | 1.00 | MEN1 (0.46) | MEN1KMT2ASLC1A1NR4A2HCAR2 | |
| SCHEMBL6448 | 0.81 | HCAR2 (0.44) | KMT2AHCAR2ALDH1A1MAOBNPC1 | |
| SCHEMBL31503070 | 0.81 | HCAR2 (0.44) | KMT2AHCAR2ALDH1A1MAOBNPC1 | |
| SCHEMBL19182700 | 0.81 | CYP2C19 (0.42) | MEN1KMT2AALDH1A1L3MBTL1NPC1 | |
| SCHEMBL30601850 | 0.80 | SSTR4 (0.53) | KMT2APOLBALDH1A1METAP2MAOB | |
| SCHEMBL26123313 | 0.80 | HSD11B1 (0.51) | MEN1KMT2ANR4A2HCAR2POLB | |
| SCHEMBL30601825 | 0.80 | HSD11B1 (0.51) | MEN1KMT2ANR4A2HCAR2POLB | |
| SCHEMBL1178048 | 0.80 | MAOA (0.46) | ALDH1A1MAOB | |
| SCHEMBL26127865 | 0.80 | SSTR4 (0.53) | KMT2APOLBALDH1A1METAP2MAOB | |
| SCHEMBL923461 | 0.80 | MAOA (0.48) | ALDH1A1HTTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4499224-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187677-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | MEN1 786/4885KMT2A 4505/4885SLC1A1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.